Search research articles
Contact Us
Filters
Showing results (1-10 of 222) with videos related to
Page
of 23
Sort By:
Annals of Internal Medicine
|
April 25, 2009
ACP Journal Club. Review: Brand-name drugs are not more effective than generic versions for treating cardiovascular disease
Braden Manns
Evidence-Based Medicine
|
June 2, 2009
Review: brand-name drugs are not more effective than generic versions for treating cardiovascular disease
Braden Manns
Circulation
|
October 26, 2018
Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease
Matthew James, Braden Manns
JAMA
|
April 13, 2011
Supplementing creatinine-based estimates of risk in chronic kidney disease: is it time?
Marcello Tonelli, Braden Manns
ACP Journal Club
|
May 2, 2006
Oral mycophenolate led to more complete remissions than intravenous cyclophosphamide for active lupus nephritis
Mike Walsh, Braden Manns
Clinical Journal of the American Society of Nephrology : CJASN
|
April 26, 2014
Do socioeconomic factors affect dialysis modality selection?
Gihad Nesrallah, Braden Manns
Seminars in Nephrology
|
September 16, 2009
Economic evaluation of dialysis therapies
Scott Klarenbach, Braden Manns
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
February 13, 2008
Optimizing the use of prescription drugs in Canada through the Common Drug Review
Mike Tierney, Braden Manns,
ACP Journal Club
|
November 4, 2006
N-acetylcysteine prevented contrast-medium-induced nephropathy in primary angioplasty
Matthew James, Braden Manns
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|
August 15, 2002
Costing health care procedures: art or science?
Gillian R Currie, Braden Manns
Page
of 23
Search research articles
Search
Showing results (1-10 of 222) with videos related to
Sort By:
Page
of 23
Annals of Internal Medicine
|
April 25, 2009
ACP Journal Club. Review: Brand-name drugs are not more effective than generic versions for treating cardiovascular disease
Braden Manns
Evidence-Based Medicine
|
June 2, 2009
Review: brand-name drugs are not more effective than generic versions for treating cardiovascular disease
Braden Manns
Circulation
|
October 26, 2018
Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease
Matthew James, Braden Manns
JAMA
|
April 13, 2011
Supplementing creatinine-based estimates of risk in chronic kidney disease: is it time?
Marcello Tonelli, Braden Manns
ACP Journal Club
|
May 2, 2006
Oral mycophenolate led to more complete remissions than intravenous cyclophosphamide for active lupus nephritis
Mike Walsh, Braden Manns
Clinical Journal of the American Society of Nephrology : CJASN
|
April 26, 2014
Do socioeconomic factors affect dialysis modality selection?
Gihad Nesrallah, Braden Manns
Seminars in Nephrology
|
September 16, 2009
Economic evaluation of dialysis therapies
Scott Klarenbach, Braden Manns
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
February 13, 2008
Optimizing the use of prescription drugs in Canada through the Common Drug Review
Mike Tierney, Braden Manns,
ACP Journal Club
|
November 4, 2006
N-acetylcysteine prevented contrast-medium-induced nephropathy in primary angioplasty
Matthew James, Braden Manns
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|
August 15, 2002
Costing health care procedures: art or science?
Gillian R Currie, Braden Manns
Page
of 23